Neurological and psychopathological sequelae associated with a lifetime intake of 40,000 ecstasy tablets.
Kouimtsidis
Christos
C
Schifano
Fabrizio
F
Sharp
Tim
T
Ford
Lisa
L
Robinson
Justin
J
Magee
Colm
C
D000328:Adult; D014150:Antipsychotic Agents / Q000008:administration & dosage; D001288:Attention / Q000187:drug effects; D001569:Benzodiazepines / Q000008:administration & dosage; D003072:Cognition Disorders / Q000139:chemically induced / Q000523:psychology; D006213:Hallucinogens / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D008297:Male; D008569:Memory Disorders / Q000139:chemically induced* / Q000188:drug therapy / Q000523:psychology; D001523:Mental Disorders / Q000139:chemically induced* / Q000188:drug therapy / Q000523:psychology; D018817:N-Methyl-3,4-methylenedioxyamphetamine / Q000008:administration & dosage / Q000009:adverse effects*; D000077152:Olanzapine; D019966:Substance-Related Disorders / Q000523:psychology*; D013997:Time Factors
D014150:Antipsychotic Agents; D006213:Hallucinogens; D001569:Benzodiazepines; D018817:N-Methyl-3,4-methylenedioxyamphetamine; D000077152:Olanzapine